PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study
Abstract Programmed cell death receptor ligand-1 (PD-L1) expression, KRAS (KRASm) and EGFR (EGFRm) mutations may influence non-small cell lung cancer (NSCLC) prognosis. We aimed to evaluate PD-L1 expression, KRASm, and EGFRm and survival among stage III unresected NSCLC patients. Using Danish regist...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-08-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-021-96486-2 |
| _version_ | 1818344253182443520 |
|---|---|
| author | Deirdre Cronin-Fenton Tapashi Dalvi Naimisha Movva Lars Pedersen Hanh Hansen Jon Fryzek Elizabeth Hedgeman Anders Mellemgaard Torben R. Rasmussen Norah Shire Stephen Hamilton-Dutoit Mette Nørgaard |
| author_facet | Deirdre Cronin-Fenton Tapashi Dalvi Naimisha Movva Lars Pedersen Hanh Hansen Jon Fryzek Elizabeth Hedgeman Anders Mellemgaard Torben R. Rasmussen Norah Shire Stephen Hamilton-Dutoit Mette Nørgaard |
| author_sort | Deirdre Cronin-Fenton |
| collection | DOAJ |
| description | Abstract Programmed cell death receptor ligand-1 (PD-L1) expression, KRAS (KRASm) and EGFR (EGFRm) mutations may influence non-small cell lung cancer (NSCLC) prognosis. We aimed to evaluate PD-L1 expression, KRASm, and EGFRm and survival among stage III unresected NSCLC patients. Using Danish registries, we collected data on stage III unresected NSCLC patients diagnosed 2001–2012 and paraffin-embedded tumor tissue from pathology archives. We assessed PD-L1 expression in tumors and tumor-infiltrating immune cells (ICs) by immunohistochemistry ( $$\ge$$ ≥ 1% threshold for PD-L1+). We genotyped KRAS and EGFR. Follow-up extended from 120 days post-diagnosis to death, emigration, or 31/12/2014. We computed median survival using Kaplan–Meier methods, and hazard ratios (HRs) using Cox regression associating the biomarkers with death, adjusting for confounders. Among 305 patients, 48% had adenocarcinoma; 38% squamous cell carcinoma. Forty-nine percent had PD-L1+ tumors—51% stage IIIA and 26% KRASm. Few (2%) patients had EGFRm. Median survival in months was 14.7 (95% CI = 11.8–17.9) and 13.4 (95% CI = 9.5–16.3) in PD-L1+ and PD-L1− tumors, respectively. KRASm was not associated with death (HR = 1.06, 95% CI = 0.74–1.51 versus wildtype). PD-L1+ tumors yielded a HR = 0.83 (95% CI = 0.63–1.10); PD-L1+ ICs a HR = 0.51 (95% CI = 0.39–0.68). Tumor expression of PD-L1 did not influence survival. PD-L1+ ICs may confer survival benefit in stage III unresected NSCLC patients. |
| first_indexed | 2024-12-13T16:43:32Z |
| format | Article |
| id | doaj.art-b4c1a9ab9ce54222a8cc1b0d41e549b9 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-13T16:43:32Z |
| publishDate | 2021-08-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-b4c1a9ab9ce54222a8cc1b0d41e549b92022-12-21T23:38:13ZengNature PortfolioScientific Reports2045-23222021-08-011111910.1038/s41598-021-96486-2PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort studyDeirdre Cronin-Fenton0Tapashi Dalvi1Naimisha Movva2Lars Pedersen3Hanh Hansen4Jon Fryzek5Elizabeth Hedgeman6Anders Mellemgaard7Torben R. Rasmussen8Norah Shire9Stephen Hamilton-Dutoit10Mette Nørgaard11Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University & Aarhus University HospitalAstraZenecaEpidStrategiesDepartment of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University & Aarhus University HospitalInstitute of Pathology, Aarhus University HospitalEpidStrategiesEpidStrategiesDepartment of Oncology, Herlev HospitalDanish Lung Cancer GroupAstraZenecaInstitute of Pathology, Aarhus University HospitalDepartment of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University & Aarhus University HospitalAbstract Programmed cell death receptor ligand-1 (PD-L1) expression, KRAS (KRASm) and EGFR (EGFRm) mutations may influence non-small cell lung cancer (NSCLC) prognosis. We aimed to evaluate PD-L1 expression, KRASm, and EGFRm and survival among stage III unresected NSCLC patients. Using Danish registries, we collected data on stage III unresected NSCLC patients diagnosed 2001–2012 and paraffin-embedded tumor tissue from pathology archives. We assessed PD-L1 expression in tumors and tumor-infiltrating immune cells (ICs) by immunohistochemistry ( $$\ge$$ ≥ 1% threshold for PD-L1+). We genotyped KRAS and EGFR. Follow-up extended from 120 days post-diagnosis to death, emigration, or 31/12/2014. We computed median survival using Kaplan–Meier methods, and hazard ratios (HRs) using Cox regression associating the biomarkers with death, adjusting for confounders. Among 305 patients, 48% had adenocarcinoma; 38% squamous cell carcinoma. Forty-nine percent had PD-L1+ tumors—51% stage IIIA and 26% KRASm. Few (2%) patients had EGFRm. Median survival in months was 14.7 (95% CI = 11.8–17.9) and 13.4 (95% CI = 9.5–16.3) in PD-L1+ and PD-L1− tumors, respectively. KRASm was not associated with death (HR = 1.06, 95% CI = 0.74–1.51 versus wildtype). PD-L1+ tumors yielded a HR = 0.83 (95% CI = 0.63–1.10); PD-L1+ ICs a HR = 0.51 (95% CI = 0.39–0.68). Tumor expression of PD-L1 did not influence survival. PD-L1+ ICs may confer survival benefit in stage III unresected NSCLC patients.https://doi.org/10.1038/s41598-021-96486-2 |
| spellingShingle | Deirdre Cronin-Fenton Tapashi Dalvi Naimisha Movva Lars Pedersen Hanh Hansen Jon Fryzek Elizabeth Hedgeman Anders Mellemgaard Torben R. Rasmussen Norah Shire Stephen Hamilton-Dutoit Mette Nørgaard PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study Scientific Reports |
| title | PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study |
| title_full | PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study |
| title_fullStr | PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study |
| title_full_unstemmed | PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study |
| title_short | PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study |
| title_sort | pd l1 expression egfr and kras mutations and survival among stage iii unresected non small cell lung cancer patients a danish cohort study |
| url | https://doi.org/10.1038/s41598-021-96486-2 |
| work_keys_str_mv | AT deirdrecroninfenton pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy AT tapashidalvi pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy AT naimishamovva pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy AT larspedersen pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy AT hanhhansen pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy AT jonfryzek pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy AT elizabethhedgeman pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy AT andersmellemgaard pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy AT torbenrrasmussen pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy AT norahshire pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy AT stephenhamiltondutoit pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy AT mettenørgaard pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy |